Multiple myeloma: Prognosis and standard treatment

Cancer Investigation

Volumn 15, Issue 1, 1997, Pages 57-64

  Oken, Martin M ^a  

^a Virginia Piper Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW;

EID: 0031036111     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709018918     Document Type: Review

References (60)

1. Durie BG, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854, 1975.
2. Salmon SE, Cassady JR: Plasma cell neoplasms. In: Cancer: Principles and Practice of Oncology, 4th ed, edited by VT DeVita Jr, S Hellman, SA Rosenberg, Philadelphia, JB Lippincott, 1993, pp 1984-2025.
3. Durie BG, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55:364-372, 1980.
4. Boccadoro M, Marmont F, Tribalto M, et al: Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol 7:119-125, 1989.
5. Greipp PR, Witzig TE: Cell kinetics in plasma cell myeloma. In: Manual of Clinical Laboratory Immunology, 4th ed, edited by NR Rose, E Conway de Macario, JL Fahey, et al, Washington, DC, American Society of Microbiology, 1992, pp 96-102.
6. Greipp PR, Oken MM, Kalish LA, et al: Independent prognostic value for plasma cell labeling index and beta 2-microglobulin in Eastern Cooperative Oncology Group myeloma Trial E9487. Proc Am Soc Clin Oncol 11:357, 1992.
7. Norfolk D, Child J A, Cooper EH, et al: Serum beta 2-microglobulin in myelomatosis: Potential value in stratification and monitoring. Br J Cancer 42:510-515, 1980.
8. Cuzick J, DeStavola BL, Cooper EH, et al: Long-term prognostic value of serum beta 2-microglobulin in myelomatosis. Br J Haematol 75:506-510, 1990.
9. Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993.
10. Gaillard JP, Bataille R, Brailly H, et al: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23:820-824, 1993.
11. Greipp PR, Gaillard JP, Kalish LA, et al: Independent prognostic value for serum soluble interleukin-6 receptor in Eastern Cooperative Oncology Group myeloma trial E9487. Proc Am Soc Clin Oncol 12:404, 1993.
12. Greipp PR, Gaillard JP, Klein B, et al: Independent prognostic value for plasma cell labeling index, immunofluorescence microscopy plasma cell percent, beta 2-microglobulin, soluble interleukin-6 receptor and C-reactive protein in myeloma trial E9487. Blood 84(Suppl 1):385a, 1994.
13. Neri A, Baldini L, Trecca D, et al: P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128-135, 1993.
14. Corradini P, Ladetto M, Voena C, et al: Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood 81:2708-2713, 1993.
15. Neri A, Murphy JP, Cro L, et al: ras oncogene mutation in multiple myeloma J Exp Med 170:1715-1725, 1989.
16. Simonsson B, Kallander CFR, Brenning G, et al: Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br J Haem atol 61:215-224, 1985.
17. Dimopoulos MA, Barlogie B, Smith TL, et al: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115:931-935, 1991.
18. Greipp PR, Raymond NM, Kyle RA, et al: Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 65:305-310, 1985.
19. Greipp PR, Bennett JM, Gaillard JP, et al: Poor survival in plasmablastic myeloma in Eastern Cooperative Oncology Group Study E9487: Cell kinetic, ploidy, biological marker and clinical correlations. Proc Am Soc Clin Oncol 14:426, 1995.
20. Alexanian R, Bonnet J, Gehan E, et al: Combination chemotherapy lor multiple myeloma. Cancer 30:382-389, 1972.
21. Alexanian R, Haut A, Khan AU, et al: Treatment of multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685, 1969.
22. Oken MM:Multiple myeloma. Med Clin North Am 68:757-787, 1984.
23. Case DC, Lee BJ, Clarkson BD: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63: 897-903, 1977.
24. Oken MM, Tsiatis A, Abramson N, et al: Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma. Proc Am Soc Clin Oncol 3:270, 1984.
25. Oken MM: Standard treatment of multiple myeloma. Mayo Clin Proc 69:781-786,1994.
26. Salmon SE, Haut A, Bonnett JD, et al: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1:453-461, 1983.
27. Salmon SE, Tesh D, Crowley J, et al: Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 8:1575-1584, 1990.
28. MacLennan ICM, Chapman C, Dunn J, et al: Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 339:200-205, 1992.
29. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 10:334-342, 1992.
30. Abramson N, Lurie P, Mietlowski WL, et al: Phase III study of intermittent carmustine, cyclophosphamide and prednisone vs. intermittent melphalan and prednisone in myeloma. Cancer Treat Rep 66:1273-1277, 1982.
31. Cohen HJ, Silberman HR, Tornyos K, et al: Comparison of two long-term chemotherapy regimens with or without agents to modify skeletal repair, in multiple myeloma. Blood 63:630-648, 1984.
32. Cooper MR, McIntyre OR, Propert KJ, et al: Single, sequential, and multiple alkylating agent therapy for multiple myeloma: A CALGB study. J Clin Oncol 4:1331-1339, 1986.
33. Harley JB, Pajak TF, McIntyre OR, et al: Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB. Blood 54:13-22, 1979.
34. Pavlovsky S, Corrado C, Santarelli MT, et al: An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three-and five-drug combinations: An Argentine Group for the Treatment of Acute Leukemia study. J Clin Oncol 6:769-775, 1988.
35. Hjorth M, Hellquist L, Holmberg E, et al: Initial treatment in multiple myeloma: No advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 74:185-191, 1990.
36. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444-448, 1991.
37. Bergsagel DE, Bailey AJ, Langley GR, et al: The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301:743-748, 1979.
38. Peest D, Deicher, H, Coldewey R, et al: Induction and maintenance therapy in multiple myeloma: A multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 24:1061-1067, 1988.
39. Buyse M, Piedbois P: Meta-analyses, use and misuse. J Clin Oncol 11:383, 1993.
40. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992.
41. Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 12:2405-2414, 1994.
42. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86-89, 1990.
43. Mellstedt H, Ahre A, Bjorkholm M, et al: Interferon therapy in myelomatosis. Lancet 1:245-247, 1979.
44. Alexanian R, Gutterman J, Levy H: Interferon treatment for multiple myteloma. Clin Haematol 11:211-220, 1982.
45. Oken MM, Kyle RA, Kay NE, et al: Interferon in the treatment of refractory multiple myeloma: An Eastern Cooperative Oncology Group study. Leuk Lymphoma 1:95-100, 1990.
46. Quesada JR, Alexanian R, Hawkins M, et al: Treatment of multiple myeloma with recombinant α-interteron. Blood 67:275-278, 1986.
47. Cooper MR, Dear K, McIntyre OR, et al: A randomized clinical trial comparing melphalan/prednisone with or without interferon alpha-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study. J Clin Oncol 11:155-160, 1993.
48. Osterborg A, Bjorkholm M, Bjoreman M, et al: Natural interferon-α in combination with melphalan/prednisone versus melphalan/ prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden. Blood 81:1428-1434, 1993.
49. Oken MM, Kyle RA, Greipp PR, et al: Possible survival benefit with chemotherapy plus interferon (rIFNα2) in the treatment of multiple myeloma. Proc Am Soc Clin Oncol 11:358, 1992.
50. Oken MM, Kyle RA, Greipp PR, et al: Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2h) in patients with multiple myeloma. Leuk Lymphoma 20:447-452, 1996.
51. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430-1434, 1990.
52. Avvisati G, Boccadoro M, Petrucci MT, et al: Interferon alpha as maintenance treatment in multiple myeloma: The Italian experience. In: Program and Abstracts of the IV International Workshop on Multiple Myeloma, Rochester, MN, Oct 2-5, 1993, pp 87-88 (abstract).
53. Westin J: Interferon therapy during the plateau phase of multiple myeloma: An update of a Swedish multicenter study. Semin Oncol 18(Suppl 7):37-40, 1991.
54. Browman GP, Rubin S, Walker I, et al: Interferon alpha 2b maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma: Results of a randomized trial. Proc Am Soc Clin Oncol 13:408, 1994.
55. Ludwig H, Cohen AM, Huber H, et al: Interferon with VMCP compared to VMCP for induction and IFN compared to control for remission maintenance in multiple myeloma. Proc Am Soc Clin Oncol 13:408, 1994.
56. Joshua DE, Penny R, Baldwin R, et al: The study of combination therapy plus or minus Roferon A in multiple myeloma. Blood 84(Suppl 1):179a, 1994.
57. Peest D, Bartels H, Bartl R, et al: Melphalan/prednisone versus polychemotherapy for remission induction and interferon A for maintenance treatment in multiple myeloma: A trial of the German Myeloma Treatment Group. In: Program and Abstracts of the IV International Workshop of Multiple Myeloma, Rochester, MN, Oct 2-5, 1993 (abstract).
58. Powles R, Cunningham D, Malpas JS, et al: A randomised trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma. Blood 84(Suppl 1):535a, 1994.
59. Jagannath S, Crowley J, Vesole D, et al: Interferon-α may improve event-free (EFS) and overall survival (OS) in multiple myeloma following double autotransplants. Proc Am Soc Clin Oncol 14:425, 1995.
60. Palumbo A, Boccadoro M, Garino LA, et al: Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma. Acta Haematol 90:71-76, 1993.